{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/40540"],"location":["China"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Clinical data analysis of bevacizumab-induced hypertension in patients with colorectal cancer","description":"Interventions: None:None\nPrimary outcome(s): Blood pressure;Overall survival;Progress-free survival;Blood pressure from 2 months before treatment to 6 months after treatment, or before treatment with other VEGF inhibitors and other pressors;The use of bevacizumab, atropine, irinotecan and antihypertensive drugs\nStudy Design: Sequential","dates":{"creation":"2022-07-15"},"accession":"40540","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2200061510"]}}